Cargando…
PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level
Facioscapulohumeral muscular dystrophy (FSHD) is a prevalent, incurable skeletal myopathy. The condition is linked to hypomethylation of the D4Z4 macrosatellite repeat at chromosome 4q35, leading to epigenetic derepression of the transcription factor DUX4; coupled with a permissive 4qA haplotype sup...
Autores principales: | Banerji, Christopher R S, Zammit, Peter S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586142/ https://www.ncbi.nlm.nih.gov/pubmed/31067297 http://dx.doi.org/10.1093/hmg/ddz043 |
Ejemplares similares
-
DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation
por: Banerji, Christopher R S, et al.
Publicado: (2020) -
Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
por: Lu-Nguyen, Ngoc, et al.
Publicado: (2021) -
Therapeutic Strategies Targeting DUX4 in FSHD
por: Le Gall, Laura, et al.
Publicado: (2020) -
An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy
por: Cowley, Matthew V, et al.
Publicado: (2023) -
Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?
por: Joubert, Romains, et al.
Publicado: (2020)